| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Judit Lazar. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716145. |
in this paper we present a critical review on psychopharmacological boundaries of schizophrenia with concurrent cannabis use. |
2013-03-25 |
2023-08-12 |
Not clear |
| Judit Lazar. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716145. |
the relevant data available in the literature suggest that a weaker compliance, poorer therapy response and higher sensitivity for extrapyramidal side effects are key features of schizophrenia and comorbid cannabis use disorder and represent a clinical challenge. |
2013-03-25 |
2023-08-12 |
Not clear |
| Judit Lazar. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716145. |
because of paucity of available research in the field there is not enough evidence to clearly depict the exact psychopharmacological profile of cannabis related schizophrenia. |
2013-03-25 |
2023-08-12 |
Not clear |
| Raquel Levin, Valeria Almeida, Fernanda Fiel Peres, Mariana Bendlin Calzavara, Neide Derci da Silva, Mayra Akimi Suiama, Suzy Tamie Niigaki, Antonio Waldo Zuardi, Jaime Eduardo Cecilio Hallak, Jose Alexandre Crippa, Vanessa Costhek Abíli. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716146. |
antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. |
2013-03-25 |
2023-08-12 |
rat |
| F Markus Lewek. Anandamide dysfunction in prodromal and established psychosis. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716147. |
it has been hypothesized nearly two decades ago that the ecb system may play a pathophysiological role in schizophrenia either in terms of an endogenous malfunction of the system itself and/or of a secondary malfunction as a result of the use of exogenous cannabinoids like Δ(9)-tetrahydrocannabinol, the major psychoactive phytocannabinoid in cannabis sativa. |
2013-03-25 |
2023-08-12 |
Not clear |
| Giovanni Martinotti, Giuseppe Di Iorio, Gianna Sepede, Domenico De Berardis, Luisa De Risio, Massimo Di Giannantoni. Cannabis use and psychosis: theme introduction. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716149. |
chronic cannabis use, especially of new synthetic varieties, may trigger psychosis and precipitate schizophrenia in vulnerable individuals. |
2013-03-25 |
2023-08-12 |
Not clear |
| Giovanni Martinotti, Giuseppe Di Iorio, Gianna Sepede, Domenico De Berardis, Luisa De Risio, Massimo Di Giannantoni. Cannabis use and psychosis: theme introduction. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716149. |
basic symptoms may possibly be a marker for the development of full schizophrenia in cannabis users and their recognition may play a role in prevention strategies. |
2013-03-25 |
2023-08-12 |
Not clear |
| Nicholas Myles, Hannah Newall, Olav Nielssen, Matthew Larg. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716150. |
the association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. |
2013-03-25 |
2023-08-12 |
Not clear |
| Nicholas Myles, Hannah Newall, Olav Nielssen, Matthew Larg. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716150. |
we aimed to use meta-analysis to compare the extent to which cannabis and tobacco use are each associated with an earlier age at onset of schizophrenia and other psychoses. |
2013-03-25 |
2023-08-12 |
Not clear |
| Nicholas Myles, Hannah Newall, Olav Nielssen, Matthew Larg. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716150. |
the electronic databases medline, embase, psycinfo and isi web of science, were searched for english-language peer-reviewed publications that reported age at onset of schizophrenia and other psychoses separately for cannabis users and non-users, or for tobaccosmokers and non-smokers. |
2013-03-25 |
2023-08-12 |
Not clear |
| Nicholas Myles, Hannah Newall, Olav Nielssen, Matthew Larg. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716150. |
this supports the hypothesis that, in some patients, cannabis use plays a causal role in the development of schizophrenia and raises the possibility of treating schizophrenia with new pharmacological treatments that have an affinity for endo-cannabinoid receptors. |
2013-03-25 |
2023-08-12 |
Not clear |
| Jose Maria Pelayo-Terán, Paula Suárez-Pinilla, Nicholas Chadi, Benedicto Crespo-Facorr. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716151. |
cannabis use may be considered as an additional risk factor in a diathesis-stress model of schizophrenia where the risk of developing the illness would be higher in genetic vulnerable people. |
2013-03-25 |
2023-08-12 |
Not clear |
| Jose Maria Pelayo-Terán, Paula Suárez-Pinilla, Nicholas Chadi, Benedicto Crespo-Facorr. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716151. |
the present review will focus on the interaction between genes and cannabis exposure in the development of psychotic symptoms and schizophrenia and the biological mechanisms of cannabis. |
2013-03-25 |
2023-08-12 |
Not clear |
| Patrik Roser, Ida S Haussleite. Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716153. |
several lines of experimental and clinical evidence point to a close relationship between cannabis, the endogenous cannabinoid system, and schizophrenia. |
2013-03-25 |
2023-08-12 |
human |
| Miguel Ruiz-Veguilla, Luis F Callado, Maite Ferri. Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716154. |
although neurological soft signs (nsss) have been consistently associated with schizophrenia and a variety of risk factors, few studies have focused on the association between nsss and environmental factors such as cannabis use, particularly in patients with first episode psychosis (fep). |
2013-03-25 |
2023-08-12 |
Not clear |
| Charlotte Rapp, Hilal Bugra, Anita Riecher-Rössler, Corinne Tamagni, Stefan Borgward. Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716152. |
it is unclear yet whether cannabis use is a moderating or causal factor contributing to grey matter alterations in schizophrenia and the development of psychotic symptoms. |
2013-03-25 |
2023-08-12 |
human |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
neurocognitive functioning and cannabis use in schizophrenia. |
2013-03-25 |
2023-08-12 |
Not clear |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
cannabis is the most prevalent illicit substance used among schizophrenia patients. |
2013-03-25 |
2023-08-12 |
Not clear |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
the effects of cannabis are mediated through the endocannabinoid system, which is a major regulator of neurotransmission and may be disturbed in schizophrenia. |
2013-03-25 |
2023-08-12 |
Not clear |
| Aviv Segev, Shaul Lev-Ra. Neurocognitive functioning and cannabis use in schizophrenia. Current pharmaceutical design. vol 18. issue 32. 2013-03-25. PMID:22716156. |
though cognitive impairment in schizophrenia is well established, the effects of cannabis on cognition in schizophrenia patients are still unclear. |
2013-03-25 |
2023-08-12 |
Not clear |